Compare CDRO & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDRO | BNR |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | Luxembourg | China |
| Employees | 325 | N/A |
| Industry | Services-Misc. Amusement & Recreation | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 363.1M | 252.7M |
| IPO Year | N/A | 2019 |
| Metric | CDRO | BNR |
|---|---|---|
| Price | $9.13 | $21.60 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | 11.3K | ★ 30.5K |
| Earning Date | 02-28-2023 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.31 | $111.65 |
| Revenue Next Year | $6.75 | N/A |
| P/E Ratio | $305.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.18 | $2.18 |
| 52 Week High | $8.91 | $41.72 |
| Indicator | CDRO | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 78.38 | 55.27 |
| Support Level | $7.78 | $19.72 |
| Resistance Level | N/A | $23.42 |
| Average True Range (ATR) | 0.32 | 1.39 |
| MACD | 0.05 | 0.94 |
| Stochastic Oscillator | 67.69 | 77.46 |
Codere Online Luxembourg SA is an international online casino gaming and online sports betting group focused on providing its customers with a safe and enjoyable online gaming experience. It currently operates in Spain, Mexico, Colombia, and Other countries. where it offers its users the ability to play online casino games and bet on sports events. Online casino offerings include the full portfolio of games typically available in land-based casinos, gaming halls and gambling establishments, such as slot machines, table games, and bingo. Online sports betting involves a user placing a wager on an event at some fixed odds determined by Codere Online. The company derives maximum revenue from Mexico.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.